These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37068931)

  • 21. Smoking does not influence disability accumulation in primary progressive multiple sclerosis.
    Javizian O; Metz LM; Deighton S; Koch MW
    Eur J Neurol; 2017 Apr; 24(4):624-630. PubMed ID: 28239937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS.
    Lorscheider J; Jokubaitis VG; Spelman T; Izquierdo G; Lugaresi A; Havrdova E; Horakova D; Trojano M; Duquette P; Girard M; Prat A; Grand'Maison F; Grammond P; Pucci E; Boz C; Sola P; Ferraro D; Spitaleri D; Lechner-Scott J; Terzi M; Van Pesch V; Iuliano G; Bergamaschi R; Ramo-Tello C; Granella F; Oreja-Guevara C; Butzkueven H; Kalincik T;
    Neurology; 2017 Sep; 89(10):1050-1059. PubMed ID: 28794248
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural history of primary progressive multiple sclerosis.
    Koch M; Kingwell E; Rieckmann P; Tremlett H
    Neurology; 2009 Dec; 73(23):1996-2002. PubMed ID: 19996074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early Clinical Features, Time to Secondary Progression, and Disability Milestones in Polish Multiple Sclerosis Patients.
    Rzepiński Ł; Zawadka-Kunikowska M; Maciejek Z; Newton JL; Zalewski P
    Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31159275
    [No Abstract]   [Full Text] [Related]  

  • 25. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical course of multiple sclerosis and labour-force absenteeism: a longitudinal population-based study.
    Castelo-Branco A; Landfeldt E; Svedbom A; Löfroth E; Kavaliunas A; Hillert J
    Eur J Neurol; 2019 Apr; 26(4):603-609. PubMed ID: 30414299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis.
    Portaccio E; Fonderico M; Iaffaldano P; Pastò L; Razzolini L; Bellinvia A; De Luca G; Ragonese P; Patti F; Brescia Morra V; Cocco E; Sola P; Inglese M; Lus G; Pozzilli C; Maimone D; Lugaresi A; Gazzola P; Comi G; Pesci I; Spitaleri D; Rezzonico M; Vianello M; Avolio C; Logullo FO; Granella F; Salvetti M; Zaffaroni M; Lucisano G; Filippi M; Trojano M; Amato MP;
    JAMA Neurol; 2022 Sep; 79(9):869-878. PubMed ID: 35877104
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis.
    Signori A; Izquierdo G; Lugaresi A; Hupperts R; Grand'Maison F; Sola P; Horakova D; Havrdova E; Prat A; Girard M; Duquette P; Boz C; Grammond P; Terzi M; Singhal B; Alroughani R; Petersen T; Ramo C; Oreja-Guevara C; Spitaleri D; Shaygannejad V; Butzkueven H; Kalincik T; Jokubaitis V; Slee M; Fernandez Bolaños R; Sanchez-Menoyo JL; Pucci E; Granella F; Lechner-Scott J; Iuliano G; Hughes S; Bergamaschi R; Taylor B; Verheul F; Edite Rio M; Amato MP; Sajedi SA; Majdinasab N; Van Pesch V; Sormani MP; Trojano M
    Mult Scler; 2018 Apr; 24(5):642-652. PubMed ID: 28382837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Profile of Polish patients with primary progressive multiple sclerosis.
    Brola W; Sobolewski P; Żak M; Flaga S; Fudala M; Siutka D; Kapica K; Chorąży M; Kułakowska A; Perenc A; Bartosik-Psujek H; Psujek M; Głąbiński A; Pawełczyk M; Gacek S; Potemkowski A
    Mult Scler Relat Disord; 2019 Aug; 33():33-38. PubMed ID: 31146082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and laboratory features of primary progressive and secondary progressive MS.
    Bashir K; Whitaker JN
    Neurology; 1999 Sep; 53(4):765-71. PubMed ID: 10489038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to ibudilast treatment according to progressive multiple sclerosis disease phenotype.
    Goodman AD; Fedler JK; Yankey J; Klingner EA; Ecklund DJ; Goebel CV; Bermel RA; Chase M; Coffey CS; Klawiter EC; Naismith RT; Fox RJ;
    Ann Clin Transl Neurol; 2021 Jan; 8(1):111-118. PubMed ID: 33460301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Progression rates and sample size estimates for PPMS based on the CLIMB study population.
    Raghavan K; Healy BC; Carruthers RL; Chitnis T
    Mult Scler; 2015 Feb; 21(2):180-8. PubMed ID: 25070676
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
    Abdelhak A; Antweiler K; Kowarik MC; Senel M; Havla J; Zettl UK; Kleiter I; Hoshi MM; Skripuletz T; Haarmann A; Stahmann A; Huss A; Gingele S; Krumbholz M; Selge C; Friede T; Ludolph AC; Overell J; Koendgen H; Clinch S; Wang Q; Ziemann U; Hauser SL; Kümpfel T; Green AJ; Tumani H
    Mult Scler Relat Disord; 2024 Jan; 81():105139. PubMed ID: 38000130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preferential spinal cord volume loss in primary progressive multiple sclerosis.
    Tsagkas C; Magon S; Gaetano L; Pezold S; Naegelin Y; Amann M; Stippich C; Cattin P; Wuerfel J; Bieri O; Sprenger T; Kappos L; Parmar K
    Mult Scler; 2019 Jun; 25(7):947-957. PubMed ID: 29781383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors.
    Iaffaldano P; Lucisano G; Patti F; Brescia Morra V; De Luca G; Lugaresi A; Zaffaroni M; Inglese M; Salemi G; Cocco E; Conte A; Ferraro D; Galgani S; Bergamaschi R; Pozzilli C; Salvetti M; Lus G; Rovaris M; Maniscalco GT; Logullo FO; Paolicelli D; Achille M; Marrazzo G; Lovato V; Comi G; Filippi M; Amato MP; Trojano M;
    Mult Scler; 2021 Mar; 27(3):430-438. PubMed ID: 33210986
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural history of primary progressive multiple sclerosis.
    Ebers GC
    Mult Scler; 2004 Jun; 10 Suppl 1():S8-13; discussion S13-5. PubMed ID: 15218804
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relapses and disability accumulation in progressive multiple sclerosis.
    Paz Soldán MM; Novotna M; Abou Zeid N; Kale N; Tutuncu M; Crusan DJ; Atkinson EJ; Siva A; Keegan BM; Pirko I; Pittock SJ; Lucchinetti CF; Weinshenker BG; Rodriguez M; Kantarci OH
    Neurology; 2015 Jan; 84(1):81-8. PubMed ID: 25398229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modelling the natural history of primary progressive multiple sclerosis.
    Harding KE; Wardle M; Moore P; Tomassini V; Pickersgill T; Ben-Shlomo Y; Robertson NP
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):13-9. PubMed ID: 24828900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Employment and absenteeism in working-age persons with multiple sclerosis.
    Salter A; Thomas N; Tyry T; Cutter G; Marrie RA
    J Med Econ; 2017 May; 20(5):493-502. PubMed ID: 28035846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.